Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Multiple Myeloma × Heparin × Clear all

Phase

Status

Withdrawn 1 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Thrombosis 1 Neoplasms, Plasma Cell 1 Neoplasms 1 Multiple Myeloma 1 Metabolic Diseases 1 Hematologic Neoplasms 1 Catheter-Related Infections 1 Bacteremia 1 Anemia, Aplastic 1

Interventions

Dexamethasone 91 Bortezomib 54 Cyclophosphamide 44 Lenalidomide 41 Calcium Dobesilate 39 Melphalan 28 pomalidomide 26 fludarabine 22 Filgrastim 21 carfilzomib 20 fludarabine phosphate 16 daratumumab 16 Whole-Body Irradiation 14 Granulocyte Colony-Stimulating Factor 14 dexamethasone acetate 13 Mycophenolic Acid 13 Antilymphocyte Serum 13 Thalidomide 12 Cyclosporine 12 Peripheral Blood Stem Cell Transplantation 11 Tacrolimus 10 Busulfan 10 dexamethasone 21-phosphate 9 auricularum 9 Radiotherapy 9 belantamab mafodotin 8 Rituximab 8 Etoposide 8 pembrolizumab 7 ixazomib 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00790842 2018-10-24

PrE1003

PrECOG, LLC.

Phase 1/2 Terminated

63 enrolled 14 charts

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡